Event
Neuralink receives Health Canada approval for CAN-PRIME Study
Key points
- Neuralink received Health Canada approval to launch CAN-PRIME, its first international clinical trial.
- CAN-PRIME extends evaluation of the N1 Implant and R1 Robot system outside the United States.
- The trial studies safety and early effectiveness of Neuralink's implant and surgical robot system.
Company context
Neuralink is a neurotechnology company developing implantable brain-computer interfaces for people with unmet medical needs, beginning with device control for people with paralysis. Its system combines the N1 Implant, external software, wireless communication, and the R1 surgical robot used to place ultra-fine electrode threads in the brain.
Context
- Company
- Neuralink
- Segment
- Healthcare
- Event type
- Regulatory
- Geography
- Fremont · United States